New drug miRisten targets Tough-to-Treat leukemia in early trial
NCT ID NCT07025564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatments. The drug works by blocking a molecule that helps cancer cells grow. The main goal is to check safety and find the best dose, while also watching for any signs that the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
miRisten (a drug that blocks a molecule called microRNA-126, which may help stop cancer cell growth)
What this could lead to
If it works, this could point toward a new treatment option for patients with AML that has returned or not responded to standard therapy.
What could go wrong
This is a very early (phase 1) trial with only 12 participants, so it is primarily testing safety and dosing. It may not show clear benefit, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact